IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments

 

IDYA: 37% | IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02 Trial Of Darovasertib Plus Crizotinib In HLA-A*02:01-Negative Metastatic Uveal Melanoma Met Primary Endpoint

 

PLCE: -20% | Children's Place Q4 Adj. EPS $(1.86) Misses $(0.96) Estimate, Sales $329.233M Miss $358.270M Estimate